Latest Breaking News On - Precision diabetes inc - Page 1 : vimarsana.com
Share this article
Share this article
RALEIGH, N.C., April 15, 2021 /PRNewswire/ -- Precision Diabetes, Inc. (PDI), an emerging leader in precision diabetes diagnostics, announced results today from a study on its Precision IGT prediabetes test at the Precision Diabetes Medicine 2021 Conference, the annual research symposium of the Precision Medicine in Diabetes Initiative (PMDI) -- a joint effort of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
The study, "Serum Alpha-Hydroxybutyrate (AHB) Predicts Elevated 1-Hour Glucose Levels in Normoglycemic Patients," was designed to assess the predictive value of AHB for impaired glucose tolerance as measured by the 1-hour oral glucose tolerance test (OGTT). Utilizing a proprietary algorithm that incorporates AHB and predicts 1-hour glucose levels greater than 155 mg/dL, Precision IGT was strongly predictive of abnormalities in glucose regulation, even after controlling for known risk factors such as fasting glucose, HbA1c, age, gender, and BMI. The data also showed that Precision IGT predicted impaired early insulin response during the 1-hour OGTT even in patients with normal fasting glucose and HbA1c levels.
MexicoAustraliaUnited-statesNorth-carolinaRaleighAmericanJacqueline-madejczykEuropean-association-for-the-study-of-diabetesTrue-health-liquidating-trustPrecision-medicine-in-diabetes-initiativeAmerican-diabetes-associationTrue-health-diagnostics